Bayer 19244- Refine: Regorafenib Observational Study In Hepatocellular Carcinoma
Posted Date: Jun 11, 2019
- Investigator: Olugbenga Olowokure
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to evaluate the safety of regorafenib in patients with uHCC, including incidence of all treatment-emergent adverse events (TEAEs) and dose modifications due to TEAEs in real-world practice conditions
Criteria:
To Be Eligible: Patients Have Confirmed Diagnoses Of Hepatocellular Carcinoma, No Past Treatment With Regorafenib
Keywords:
Hepatocellular Carcinoma, Liver Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com